As China's economy keeps growing, people's interest in the health and drug industries have been rising. China's drug market continues to expand and has become the second largest market after the United States, which makes China an attractive investment place for global pharmaceutical enterprises. Many drug enterprises from Europe, the US, Japan, etc. are keen to enter China's market.
China might have a different market culture and regulatory system compared to other countries. What could be the concerns with business collaboration and regulatory compliance for foreign companies?
How big on earth is China's pharmaceutical market?
What collaborative transaction modes are commonest in China?
What are the therapeutic areas that Chinese pharmaceutical companies are most interested in?
What should foreign pharmaceutical companies prepare before entering the Chinese market?
What are the main opportunities and challenges faced during the product introduction?
To answer your questions, we have invited Mr. Zhou Feng from Haisco Pharmaceutical Group, to give a speech on "How Can Foreign Medical Products Embrace the Chinese Market", In this webinar, Mr. Zhou Feng will start with the overview of Chinese pharmaceutical market. Then he will summarize the collaborative transactions, and eventually specify the concerns of Chinese companies and consideration for cooperation, including product, intellectual property, enterprise, business mode and mutual understanding and enduring patience.